KACEY LOHMANN: Open Payments
NPI 1962861930 · GILBERT, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,352 in 36 payments from 13 companies in 2025. Trend: 2023 $543 · 2024 $245 · 2025 $1,352
Food & beverage: $1,352
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 6 | $298 |
| Janssen Biotech, Inc. | 7 | $253 |
| Phathom Pharmaceuticals, Inc. | 4 | $189 |
| GENZYME CORPORATION | 3 | $159 |
| Gilead Sciences, Inc. | 3 | $127 |
| ABBVIE INC. | 4 | $91 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $52 |
| Ipsen Biopharmaceuticals, Inc | 2 | $40 |
| QOL Medical, LLC | 1 | $37 |
| Ardelyx, Inc. | 1 | $32 |
Products named: REZDIFFRA, TREMFYA, VOQUEZNA, DUPIXENT, RINVOQ, Linzess, IQIRVO, Sucraid.
Industry payments across AZ — which companies pay providers there.
